المؤلفون: Marieke Walma, Laura Maggino, F. Jasmijn Smits, Alicia S. Borggreve, Lois A. Daamen, Vincent P. Groot, Fabio Casciani, Vincent E. de Meijer, Frank J. Wessels, George P. van der Schelling, Vincent B. Nieuwenhuijs, Koop Bosscha, Erwin van der Harst, Ronald van Dam, Mike S. Liem, Sebastiaan Festen, Martijn W. J. Stommel, Daphne Roos, Fennie Wit, Ignace H. de Hingh, Bert A. Bonsing, Olivier R. Busch, Bas Groot Koerkamp, Geert Kazemier, Marc G. Besselink, Roberto Salvia, Giuseppe Malleo, I. Quintus Molenaar, Hjalmar C. van Santvoort

المصدر: Journal of Clinical Medicine, Vol 13, Iss 6, p 1679 (2024)

مصطلحات موضوعية: pancreatic cancer, occult metastases, prediction model, Medicine

الوصف: Occult metastases are detected in 10–15% of patients during exploratory laparotomy for pancreatic cancer. This study developed and externally validated a model to predict occult metastases in patients with potentially resectable pancreatic cancer. Model development was performed within the Dutch Pancreatic Cancer Audit, including all patients operated for pancreatic cancer (January 2013–December 2017). Multivariable logistic regression analysis based on the Akaike Information Criteria was performed with intraoperative pathologically proven metastases as the outcome. The model was externally validated with a cohort from the University Hospital of Verona (January 2013–December 2017). For model development, 2262 patients were included of whom 235 (10%) had occult metastases, located in the liver (n = 143, 61%), peritoneum (n = 73, 31%), or both (n = 19, 8%). The model included age (OR 1.02, 95% CI 1.00–1.03), BMI (OR 0.96, 95% CI 0.93–0.99), preoperative nutritional support (OR 1.73, 95% CI 1.01–2.74), tumor diameter (OR 1.60, 95% CI 1.04–2.45), tumor composition (solid vs. cystic) (OR 2.33, 95% CI 1.20–4.35), and indeterminate lesions on preoperative imaging (OR 4.01, 95% CI 2.16–7.43). External validation showed poor discrimination with a C-statistic of 0.56. Although some predictor variables were significantly associated with occult metastases, the model performed insufficiently at external validation.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2077-0383/13/6/1679Test; https://doaj.org/toc/2077-0383Test

الوصول الحر: https://doaj.org/article/09bd235be44f4ef785712079fb333204Test

المؤلفون: Thijs de Rooij, Jony van Hilst, Jantien A. Vogel, Hjalmar C. van Santvoort, Marieke T. de Boer, Djamila Boerma, Peter B. van den Boezem, Bert A. Bonsing, Koop Bosscha, Peter-Paul Coene, Freek Daams, Ronald M. van Dam, Marcel G. Dijkgraaf, Casper H. van Eijck, Sebastiaan Festen, Michael F. Gerhards, Bas Groot Koerkamp, Jeroen Hagendoorn, Erwin van der Harst, Ignace H. de Hingh, Cees H. Dejong, Geert Kazemier, Joost Klaase, Ruben H. de Kleine, Cornelis J. van Laarhoven, Daan J. Lips, Misha D. Luyer, I. Quintus Molenaar, Vincent B. Nieuwenhuijs, Gijs A. Patijn, Daphne Roos, Joris J. Scheepers, George P. van der Schelling, Pascal Steenvoorde, Rutger-Jan Swijnenburg, Jan H. Wijsman, Moh’d Abu Hilal, Olivier R. Busch, Marc G. Besselink, for the Dutch Pancreatic Cancer Group

المصدر: Trials, Vol 18, Iss 1, Pp 1-10 (2017)

مصطلحات موضوعية: Minimally invasive, Laparoscopic, Robot-assisted, Distal pancreatectomy, Pancreatic surgery, Pancreatic cancer, Medicine (General), R5-920

الوصف: Abstract Background Observational cohort studies have suggested that minimally invasive distal pancreatectomy (MIDP) is associated with better short-term outcomes compared with open distal pancreatectomy (ODP), such as less intraoperative blood loss, lower morbidity, shorter length of hospital stay, and reduced total costs. Confounding by indication has probably influenced these findings, given that case-matched studies failed to confirm the superiority of MIDP. This accentuates the need for multicenter randomized controlled trials, which are currently lacking. We hypothesize that time to functional recovery is shorter after MIDP compared with ODP even in an enhanced recovery setting. Methods LEOPARD is a randomized controlled, parallel-group, patient-blinded, multicenter, superiority trial in all 17 centers of the Dutch Pancreatic Cancer Group. A total of 102 patients with symptomatic benign, premalignant or malignant disease will be randomly allocated to undergo MIDP or ODP in an enhanced recovery setting. The primary outcome is time (days) to functional recovery, defined as all of the following: independently mobile at the preoperative level, sufficient pain control with oral medication alone, ability to maintain sufficient (i.e. >50%) daily required caloric intake, no intravenous fluid administration and no signs of infection. Secondary outcomes are operative and postoperative outcomes, including clinically relevant complications, mortality, quality of life and costs. Discussion The LEOPARD trial is designed to investigate whether MIDP reduces the time to functional recovery compared with ODP in an enhanced recovery setting. Trial registration Dutch Trial Register, NTR5188 . Registered on 9 April 2015

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s13063-017-1892-9Test; https://doaj.org/toc/1745-6215Test

الوصول الحر: https://doaj.org/article/48126af9caf94e8aa02a77e625589467Test

المؤلفون: Jelle C. van Dongen, Eva Versteijne, Bert A. Bonsing, J. Sven D. Mieog, Ignace H.J.T. de Hingh, Sebastiaan Festen, Gijs A. Patijn, Ronald van Dam, Erwin van der Harst, Jan H. Wijsman, Koop Bosscha, Marion van der Kolk, Vincent E. de Meijer, Mike S.L. Liem, Olivier R. Busch, Marc G.H. Besselink, Geertjan van Tienhoven, Bas Groot Koerkamp, Casper H.J. van Eijck, Mustafa Suker

المساهمون: Surgery, CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, CCA - Imaging and biomarkers, Radiotherapy, MUMC+: MA Heelkunde (9), RS: NUTRIM - R2 - Liver and digestive health, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiation Oncology

المصدر: van Dongen, J C, Versteijne, E, Bonsing, B A, Mieog, J S D, de Hingh, I H J T, Festen, S, Patijn, G A, van Dam, R, van der Harst, E, Wijsman, J H, Bosscha, K, van der Kolk, M, de Meijer, V E, Liem, M S L, Dutch Pancreatic Cancer Group, Busch, O R, Besselink, M G H, van Tienhoven, G, Groot Koerkamp, B, van Eijck, C H J & Suker, M 2023, ' The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial ', European Journal of Surgical Oncology, vol. 49, no. 4, pp. 811-817 . https://doi.org/10.1016/j.ejso.2022.12.011Test
European Journal of Surgical Oncology, 49(4), 811-817. W.B. Saunders
European journal of surgical oncology. W.B. Saunders Ltd
European Journal of Surgical Oncology, 49(4), 811-817. ELSEVIER SCI LTD
European Journal of Surgical Oncology, 49(4), 811-817. W.B. Saunders Ltd

مصطلحات موضوعية: Pancreatic ductal adenocarcinoma, Neoadjuvant treatment, Oncology, SDG 3 - Good Health and Well-being, Staging laparoscopy, Surgery, General Medicine, Pancreatic cancer

الوصف: BACKGROUND: The necessity of the staging laparoscopy in patients with pancreatic cancer is still debated. The objective of this study was to assess the yield of staging laparoscopy for detecting occult metastases in patients with resectable or borderline resectable pancreatic cancer.METHOD: This was a post-hoc analysis of the randomized controlled PREOPANC trial in which patients with resectable or borderline resectable pancreatic cancer were randomized between preoperative chemoradiotherapy or immediate surgery. Patients assigned to preoperative treatment underwent a staging laparoscopy prior to preoperative treatment according to protocol, to avoid unnecessary chemoradiotherapy in patients with occult metastatic disease.RESULTS: Of the 246 included patients, 7 did not undergo surgery. A staging laparoscopy was performed in 133 patients (55.6%) and explorative laparotomy in 106 patients (44.4%). At staging laparoscopy, occult metastases were detected in 13 patients (9.8%); 12 liver metastases and 1 peritoneal metastasis. At direct explorative laparotomy, occult metastases were found in 9 patients (8.5%); 6 with liver metastases, 1 with peritoneal metastases, and 2 with metastases at multiple sites. One patient had peritoneal metastases at exploration after a negative staging laparoscopy. Patients with occult metastases were more likely to receive palliative chemotherapy if found with staging laparoscopy compared to laparotomy (76.9% vs. 30.0%, p = 0.040).CONCLUSIONS: Staging laparoscopy detected occult metastases in about 10% of patients with resectable or borderline resectable pancreatic cancer. These patients were more likely to receive palliative systemic chemotherapy compared to patients in whom occult metastases were detected with laparotomy. A staging laparoscopy is recommended before planned resection.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05d6b4a4b53451517e0fffc5e9778595Test
https://doi.org/10.1016/j.ejso.2022.12.011Test

المؤلفون: Bert A. Bonsing, Marc G. Besselink, Geert Kazemier, Olivier R. Busch, F. Jasmijn Smits, Ignace H J T de Hingh, Sebastiaan Festen, Mark Meerdink, Erwin van der Harst, Misha Luyer, Martijn W J Stommel, Mike Liem, Marion van der Kolk, I. Quintus Molenaar, Casper H.J. van Eijck, Lois A Daamen, Ronald M. van Dam, Maaike E Verweij, C. Henri van Werkhoven, Jennifer M.J. Schreinemakers, Babs M Zonderhuis, Daphne Roos, F. Wit, Hjalmar C. van Santvoort, Bas Groot Koerkamp, Lucas Goense, Vincent E de Meijer, Vincent B. Nieuwenhuijs, Joost M. Klaase, J. Sven D. Mieog

المساهمون: Surgery, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Heelkunde (9), RS: NUTRIM - R2 - Liver and digestive health, CCA - Cancer Treatment and quality of life, AGEM - Re-generation and cancer of the digestive system

المصدر: Annals of surgery, 275(1), E222-E228. Lippincott Williams and Wilkins
Annals of Surgery, 275(1), E222-E228. LIPPINCOTT WILLIAMS & WILKINS
Annals of Surgery, 275(1), E222-E228. Lippincott Williams and Wilkins
Annals of Surgery, 275, 1, pp. e222-e228
Jasmijn Smits, F, Verweij, M E, Daamen, L A, Henri van Werkhoven, C, Goense, L, Besselink, M G, Bonsing, B A, Busch, O R, van Dam, R M, van Eijck, C H J, Festen, S, Koerkamp, B G, van der Harst, E, de Hingh, I H, Kazemier, G, Klaase, J M, van der Kolk, M, Liem, M, Luyer, M D P, Meerdink, M, Sven D. Mieog, J, Nieuwenhuijs, V B, Roos, D, Schreinemakers, J M, Stommel, M W, Wit, F, Zonderhuis, B M, de Meijer, V E, van Santvoort, H C & Quintus Molenaar, I 2022, ' Impact of Complications after Pancreatoduodenectomy on Mortality, Organ Failure, Hospital Stay, and Readmission Analysis of a Nationwide Audit ', Annals of Surgery, vol. 275, no. 1, pp. E222-E228 . https://doi.org/10.1097/SLA.0000000000003835Test
Annals of Surgery, 275, e222-e228
Annals of Surgery, 275(1), E222-E228. Lippincott Williams & Wilkins

مصطلحات موضوعية: Male, Complications, INTERNATIONAL STUDY-GROUP, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, Postoperative Complications, ADJUVANT CHEMOTHERAPY, Risk Factors, Hospital Mortality, Netherlands, education.field_of_study, OUTCOMES, Incidence, Confounding, Middle Aged, CANCER, Survival Rate, Pancreatic fistula, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, medicine.medical_specialty, POSTPANCREATECTOMY HEMORRHAGE PPH, Population, Patient Readmission, Pancreaticoduodenectomy, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Pancreatic cancer, POSTOPERATIVE PANCREATIC FISTULA, medicine, Humans, Quality improvement, education, Adverse effect, Pancreas, Aged, Retrospective Studies, Gastric emptying, business.industry, Length of Stay, medicine.disease, Surgery, Pancreatic Neoplasms, Pneumonia, DEFINITION, GEMCITABINE, Complication, business, GRADE C, Follow-Up Studies

الوصف: Contains fulltext : 251531.pdf (Publisher’s version ) (Closed access) OBJECTIVE: To quantify the impact of individual complications on mortality, organ failure, hospital stay, and readmission after pancreatoduodenectomy. SUMMARY OF BACKGROUND DATA: An initial complication may provoke a sequence of adverse events potentially leading to mortality after pancreatoduodenectomy. This study was conducted to aid prioritization of quality improvement initiatives. METHODS: Data from consecutive patients undergoing pancreatoduodenectomy (2014-2017) were extracted from the Dutch Pancreatic Cancer Audit. Population attributable fractions (PAF) were calculated for the association of each complication (ie, postoperative pancreatic fistula, postpancreatectomy hemorrhage, bile leakage, delayed gastric emptying, wound infection, and pneumonia) with each unfavorable outcome [ie, in-hospital mortality, organ failure, prolonged hospital stay (>75th percentile), and unplanned readmission), whereas adjusting for confounders and other complications. The PAF represents the proportion of an outcome that could be prevented if a complication would be eliminated completely. RESULTS: Overall, 2620 patients were analyzed. In-hospital mortality occurred in 95 patients (3.6%), organ failure in 198 patients (7.6%), and readmission in 427 patients (16.2%). Postoperative pancreatic fistula and postpancreatectomy hemorrhage had the greatest independent impact on mortality [PAF 25.7% (95% CI 13.4-37.9) and 32.8% (21.9-43.8), respectively] and organ failure [PAF 21.8% (95% CI 12.9-30.6) and 22.1% (15.0-29.1), respectively]. Delayed gastric emptying had the greatest independent impact on prolonged hospital stay [PAF 27.6% (95% CI 23.5-31.8)]. The impact of individual complications on unplanned readmission was smaller than 11%. CONCLUSION: Interventions focusing on postoperative pancreatic fistula and postpancreatectomy hemorrhage may have the greatest impact on in-hospital mortality and organ failure. To prevent prolonged hospital stay, initiatives should in addition focus on delayed gastric emptying.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fed5495f8e132144713370710c4fa8d5Test
https://hdl.handle.net/2066/251531Test

المؤلفون: Geert Kazemier, Olivier R. Busch, Lois A. Daamen, I. Q. Molenaar, Vincent E de Meijer, Vincent B. Nieuwenhuijs, Bas Groot Koerkamp, Marc G. Besselink, Hjalmar C. van Santvoort, Robert C. Verdonk, Mihaela G Raicu, Sebastiaan Festen, Geert A. Cirkel, Ronald M. van Dam, Nadia Haj Mohammad, Ignace H. J. T. de Hingh, Martijn Intven, Gert J. Meijer, Helena M. Verkooijen, Jennifer M.J. Schreinemakers, Erwin van der Harst, Maartje Los, Bobby K Pranger, Koop Bosscha, Vincent P. Groot, Martijn W J Stommel

المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Surgery, MUMC+: MA Heelkunde (9), RS: NUTRIM - R2 - Liver and digestive health, Groningen Institute for Organ Transplantation (GIOT), Center for Liver, Digestive and Metabolic Diseases (CLDM), CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

المصدر: Annals of Surgery, 275, 4, pp. 769-775
Annals of Surgery, 275(4), 769-775. LIPPINCOTT WILLIAMS & WILKINS
Annals of surgery, 275(4), 769-775. Lippincott Williams and Wilkins
Annals of Surgery, 275(4), 769-775. Lippincott Williams & Wilkins
Annals of Surgery, 275, 769-775

مصطلحات موضوعية: medicine.medical_specialty, RESECTION, pancreatic ductal adenocarcinoma, DUCTAL ADENOCARCINOMA, GUIDELINES, Asymptomatic, THERAPY, 03 medical and health sciences, disease recurrence, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Interquartile range, Internal medicine, Pancreatic cancer, ISOLATED LOCAL RECURRENCE, SURVEILLANCE, Adjuvant therapy, follow-up, Humans, Medicine, Prospective Studies, Prospective cohort study, Netherlands, Retrospective Studies, business.industry, Proportional hazards model, Hazard ratio, PDAC, Perioperative, ASSOCIATION, medicine.disease, Pancreatic Neoplasms, FOLFIRINOX, GEMCITABINE, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Surgery, Neoplasm Recurrence, Local, medicine.symptom, business, Carcinoma, Pancreatic Ductal

الوصف: OBJECTIVE: To evaluate whether detection of recurrent pancreatic ductal adenocarcinoma (PDAC) in an early, asymptomatic stage increases the number of patients receiving additional treatment, subsequently improving survival.SUMMARY OF BACKGROUND DATA: International guidelines disagree on the value of standardized postoperative surveillance for early detection and treatment of PDAC recurrence.METHODS: A nationwide, observational cohort study was performed including all patients who underwent PDAC resection (2014-2016). Prospective baseline and perioperative data were retrieved from the Dutch Pancreatic Cancer Audit. Data on follow-up, treatment, and survival were collected retrospectively. Overall survival (OS) was evaluated using multivariable Cox regression analysis, before and after propensity-score matching, stratified for patients with symptomatic and asymptomatic recurrence.RESULTS: Eight hundred thirty-six patients with a median follow-up of 37 months (interquartile range 30-48) were analyzed. Of those, 670 patients (80%) developed PDAC recurrence after a median follow-up of 10 months (interquartile range 5-17). Additional treatment was performed in 159/511 patients (31%) with symptomatic recurrence versus 77/159 (48%) asymptomatic patients (P < 0.001). After propensity-score matching on lymph node ratio, adjuvant therapy, disease-free survival, and recurrence site, additional treatment was independently associated with improved OS for both symptomatic patients [hazard ratio 0.53 (95% confidence interval 0.42-0.67); P < 0.001] and asymptomatic patients [hazard ratio 0.45 (95% confidence interval 0.29-0.70); P < 0.001].CONCLUSIONS: Additional treatment of PDAC recurrence was independently associated with improved OS, with asymptomatic patients having a higher probability to receive recurrence treatment. Therefore, standardized postoperative surveillance aiming to detect PDAC recurrence before the onset of symptoms has the potential to improve survival. This provides a rationale for prospective studies on standardized surveillance after PDAC resection.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9726c81fbaec8b7ad68e857af12a15aTest
https://repository.ubn.ru.nl/handle/2066/247921Test

المؤلفون: Ignace H. J. T. de Hingh, Lodewijk A.A. Brosens, Johanna W. Wilmink, Arantza Farina Sarasqueta, M. Liem, Marin Strijker, L. Bengt van Rijssen, Marja A. Boermeester, Jony van Hilst, Geert Kazemier, Mustafa Suker, Vincent E de Meijer, Bert A. Bonsing, Arja Gerritsen, Olivier R. Busch, Marc G. Besselink, Hjalmar C. van Santvoort, Erwin van der Harst, Judith H E Verhagen, Joanne Verheij, Cornelis J. H. M. van Laarhoven, I. Quintus Molenaar, Paul Fockens, Ronald M. van Dam, Clément J. Huysentruyt, Hanneke W. M. van Laarhoven, Casper H.J. van Eijck, Maarten F. Bijlsma, Roos Wennink, Jeanin E. van Hooft, Michael F. Gerhards, Marco J. Bruno, Frederike Dijk, Joost M. Klaase, Bas Groot Koerkamp, Hein W. Verspaget

المساهمون: Gastroenterology & Hepatology, Surgery, Graduate School, AGEM - Re-generation and cancer of the digestive system, AGEM - Digestive immunity, CCA - Imaging and biomarkers, AGEM - Endocrinology, metabolism and nutrition, Center of Experimental and Molecular Medicine, Radiotherapy, Pathology, Gastroenterology and Hepatology, Oncology, APH - Methodology, Groningen Institute for Organ Transplantation (GIOT), Value, Affordability and Sustainability (VALUE), Center for Liver, Digestive and Metabolic Diseases (CLDM), RS: NUTRIM - R2 - Liver and digestive health, MUMC+: MA Heelkunde (9)

المصدر: Pancreas, 47, 495-501
Pancreas, 47, 4, pp. 495-501
Pancreas, 47(4), 495. Lippincott Williams and Wilkins
Pancreas, 47(4), 495-501. Lippincott Williams & Wilkins
Pancreas, 47(4), 495-501
Pancreas, 47(4), 495-501. Lippincott Williams and Wilkins
PANCREAS, 47(4), 495-501. LIPPINCOTT WILLIAMS & WILKINS
Pancreas, 47(4), 495-501. LIPPINCOTT WILLIAMS & WILKINS
Strijker, M, Gerritsen, A, van Hilst, J, Bijlsma, M F, Bonsing, B A, Brosens, L A, Bruno, M J, van Dam, R M, Dijk, F, van Eijck, C H, Farina Sarasqueta, A, Fockens, P, Gerhards, M F, Groot Koerkamp, B, van der Harst, E, de Hingh, I H, van Hooft, J E, Huysentruyt, C J, Kazemier, G, Klaase, J M, van Laarhoven, C J, van Laarhoven, H W, Liem, M S, de Meijer, V E, van Rijssen, L B, van Santvoort, H C, Suker, M, Verhagen, J H, Verheij, J, Verspaget, H W, Wennink, R A, Wilmink, J W, Molenaar, I Q, Boermeester, M A, Busch, O R & Besselink, M G 2018, ' The Dutch Pancreas Biobank within the Parelsnoer Institute: A nationwide Biobank of pancreatic and periampullary diseases ', Pancreas, vol. 47, no. 4, pp. 495-501 . https://doi.org/10.1097/MPA.0000000000001018Test

مصطلحات موضوعية: Male, Endocrinology, Diabetes and Metabolism, MULTICENTER, Translational Research, Biomedical, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], PLUS GEMCITABINE, 0302 clinical medicine, Endocrinology, Bioresources, Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14], Prospective Studies, Prospective cohort study, MOLECULAR PATHOLOGY, Biological Specimen Banks, Netherlands, Academic Medical Centers, Middle Aged, OPEN-LABEL, CANCER, Biobank, Diabetes and Metabolism, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, Pancreas, Chronic pancreatitis, Ampulla of Vater, medicine.medical_specialty, Tissue and Organ Procurement, Translational research, Periampullary tumors, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, Pancreatic cancer, medicine, Internal Medicine, Journal Article, Humans, COHORT, Aged, LANDSCAPE, Hepatology, business.industry, General surgery, medicine.disease, Personalized medicine, RANDOMIZED-TRIAL, Pancreatic Neoplasms, Clinical research, TISSUE, Pancreatitis, business

الوصف: OBJECTIVES: Large biobanks with uniform collection of biomaterials and associated clinical data are essential for translational research. The Netherlands has traditionally been well organized in multicenter clinical research on pancreatic diseases, including the nationwide multidisciplinary Dutch Pancreatic Cancer Group and Dutch Pancreatitis Study Group. To enable high-quality translational research on pancreatic and periampullary diseases, these groups established the Dutch Pancreas Biobank.METHODS: The Dutch Pancreas Biobank is part of the Parelsnoer Institute and involves all 8 Dutch university medical centers and 5 nonacademic hospitals. Adult patients undergoing pancreatic surgery (all indications) are eligible for inclusion. Preoperative blood samples, tumor tissue from resected specimens, pancreatic cyst fluid, and follow-up blood samples are collected. Clinical parameters are collected in conjunction with the mandatory Dutch Pancreatic Cancer Audit.RESULTS: Between January 2015 and May 2017, 488 patients were included in the first 5 participating centers: 4 university medical centers and 1 nonacademic hospital. Over 2500 samples were collected: 1308 preoperative blood samples, 864 tissue samples, and 366 follow-up blood samples.CONCLUSIONS: Prospective collection of biomaterials and associated clinical data has started in the Dutch Pancreas Biobank. Subsequent translational research will aim to improve treatment decisions based on disease characteristics.

وصف الملف: image/pdf; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cdee080786fe92d4b411b9f2eae945cTest
https://doi.org/10.1097/mpa.0000000000001018Test

المؤلفون: Mustafa Suker, Bas Groot Koerkamp, Casper H.J. van Eijck, Yarne Klaver, Kostandinos Sideras, N. A. Aziz, Roel Haen, Daphne Roos, Bert A. Bonsing, Mohammad Hosein Aziz, J.S.D. Mieog, Katya Mauff, Erwin van der Harst, Lawlaw Saida

المساهمون: Surgery, Epidemiology, Medical Oncology

المصدر: Annals of Surgery
Annals of Surgery, 270(1), 139-146. LIPPINCOTT WILLIAMS & WILKINS
Annals of Surgery, 270(1), 139-146. Lippincott Williams & Wilkins

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, medicine.medical_treatment, pancreatic cancer, pancreatic ductal adenocarcinoma, prognostic biomarkers, survival, Gastroenterology, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Pancreatectomy, SDG 3 - Good Health and Well-being, Internal medicine, Pancreatic cancer, medicine, Carcinoma, Biomarkers, Tumor, Humans, Prospective cohort study, Lymph node, Aged, Retrospective Studies, Aged, 80 and over, Inflammation, systemic-immune-inflammation-index, business.industry, Hazard ratio, Reproducibility of Results, Retrospective cohort study, Bilirubin, Middle Aged, medicine.disease, Prognosis, Pancreatic Neoplasms, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Surgery, Female, Neoplasm Recurrence, Local, business, obstructive jaundice, Cohort study, Carcinoma, Pancreatic Ductal, Follow-Up Studies

الوصف: Objective: Our aim was to determine the prognostic significance of the systemic-immune-inflammation index (SIII) in patients with resectable pancreatic cancer, using cancer-specific survival as the primary outcome.Background: Pancreatic cancer is associated with a dysfunctional immune system and poor prognosis. We examined the prognostic significance of the SIII in patients with resectable pancreatic ductal adenocarcinoma (PDAC) and the effects of bilirubin on this index.Methods: We retrospectively assessed all pancreatic resections performed between 2004 and 2015 at 4 tertiary referral centers to identify pathologically confirmed PDAC patients. Baseline clinicopathologic characteristics, preoperative laboratory values such as absolute neutrophil, lymphocyte, and platelet counts, C-reactive protein, albumin, bilirubin, and CA19-9 levels, and also follow-up information, were collected. The associations of the calculated inflammatory indices with outcome were both internally and externally validated.Results: In all, 590 patients with resectable PDAC were included. The discovery and validation cohort included 170 and 420 patients, respectively. SIII > 900 [hazard ratio (HR) 2.32, 95% confidence interval (CI) 1.55-3.48], lymph node ratio (HR 3.75, 95% CI 2.08-6.76), and CA19.9 > 200 kU/L (HR 1.62, 95% CI 1.07-2.46) were identified as independent predictors of cancer-specific survival. Separate model analysis confirmed that preoperative SIII contributed significantly to prognostication. However, SIII appeared to lose its prognostic significance in patients with bilirubin levels above 200 mu mol/L.Conclusions: SIII is an independent predictor of cancer-specific survival and recurrence in patients with resectable PDAC. SIII may lose its prognostic significance in patients with high bilirubin levels. Properly designed prospective studies are needed to further confirm this hypothesis.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1910e0c01b3fb60e26154be57258f81Test
https://pubmed.ncbi.nlm.nih.gov/29334554Test

المؤلفون: L. Bengt van Rijssen, Bas G. Koerkamp, Maurice J. Zwart, Bert A. Bonsing, Koop Bosscha, Ronald M. van Dam, Casper H. van Eijck, Michael F. Gerhards, Erwin van der Harst, Ignace H. de Hingh, Koert P. de Jong, Geert Kazemier, Joost Klaase, Cornelis J. van Laarhoven, I. Quintus Molenaar, Gijs A. Patijn, Coen G. Rupert, Hjalmar C. van Santvoort, Joris J. Scheepers, George P. van der Schelling, Olivier R. Busch, Marc G. Besselink, Thomas L. Bollen, Marco J. Bruno, Geert-Jan van Tienhoven, Arnold Norduyn, David P. Berry, Bobby Tingstedt, Jennifer F. Tseng, Christopher L. Wolfgang

المساهمون: RS: NUTRIM - R2 - Liver and digestive health, MUMC+: MA Heelkunde (9), Surgery, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA - Cancer Treatment and Quality of Life, CCA -Cancer Center Amsterdam, Graduate School, APH - Methodology, Other departments, Radiotherapy, CCA - Cancer Treatment and quality of life, AGEM - Re-generation and cancer of the digestive system, Groningen Institute for Organ Transplantation (GIOT), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Value, Affordability and Sustainability (VALUE)

المصدر: HPB, 19(10), 919-926
HPB, 19(10), 919-926. ELSEVIER SCI LTD
HPB, 19(10), 919-926. John Wiley & Sons Inc.
Hpb, 19, 919-926
HPB: The official journal of the International Hepato Pancreato Biliary Association, 19(10), 919-926. John Wiley and Sons Inc.
HPB, 19(10), 919-926. John Wiley and Sons Inc.
van Rijssen, L B, Koerkamp, B G, Zwart, M J, Bonsing, B A, Bosscha, K, van Dam, R M, van Eijck, C H, Gerhards, M F, van der Harst, E, de Hingh, I H, de Jong, K P, Kazemier, G, Klaase, J, van Laarhoven, C J, Molenaar, I Q, Patijn, G A, Rupert, C G, van Santvoort, H C, Scheepers, J J, van der Schelling, G P, Busch, O R, Besselink, M G, Bollen, T L, Bruno, M J, van Tienhoven, G J, Norduyn, A, Berry, D P, Tingstedt, B, Tseng, J F, Wolfgang, C L & Dutch Pancreatic Cancer Group 2017, ' Nationwide prospective audit of pancreatic surgery : design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit ', HPB, vol. 19, no. 10, pp. 919-926 . https://doi.org/10.1016/j.hpb.2017.06.010Test
Hpb, 19, 10, pp. 919-926
Hpb, 19(10), 919-926. ELSEVIER SCI LTD

مصطلحات موضوعية: Male, Research design, Time Factors, Databases, Factual, INTERNATIONAL STUDY-GROUP, 030230 surgery, law.invention, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Postoperative Complications, 0302 clinical medicine, Randomized controlled trial, Risk Factors, law, Health care, HOSPITAL MORTALITY, Prospective Studies, Registries, Prospective cohort study, QUALITY IMPROVEMENT PROGRAM, Netherlands, Medical Audit, Process Assessment, Health Care, Gastroenterology, Middle Aged, ACS-NSQIP, CONTROLLED MULTICENTER TRIAL, Treatment Outcome, Research Design, ISGPS DEFINITION, 030220 oncology & carcinogenesis, Female, medicine.medical_specialty, MEDLINE, Audit, Patient Readmission, Pancreaticoduodenectomy, 03 medical and health sciences, Pancreatectomy, SDG 3 - Good Health and Well-being, Pancreatic cancer, medicine, Humans, Aged, Quality Indicators, Health Care, Hepatology, business.industry, PROSPECTIVE-RANDOMIZED-TRIAL, LENGTH-OF-STAY, RISK CALCULATOR, Length of Stay, medicine.disease, Cancer registry, Emergency medicine, business, SURGICAL QUALITY

الوصف: Item does not contain fulltext BACKGROUND: Auditing is an important tool to identify practice variation and 'best practices'. The Dutch Pancreatic Cancer Audit is mandatory in all 18 Dutch centers for pancreatic surgery. METHODS: Performance indicators and case-mix factors were identified by a PubMed search for randomized controlled trials (RCT's) and large series in pancreatic surgery. In addition, data dictionaries of two national audits, three institutional databases, and the Dutch national cancer registry were evaluated. Morbidity, mortality, and length of stay were analyzed of all pancreatic resections registered during the first two audit years. Case ascertainment was cross-checked with the Dutch healthcare inspectorate and key-variables validated in all centers. RESULTS: Sixteen RCT's and three large series were found. Sixteen indicators and 20 case-mix factors were included in the audit. During 2014-2015, 1785 pancreatic resections were registered including 1345 pancreatoduodenectomies. Overall in-hospital mortality was 3.6%. Following pancreatoduodenectomy, mortality was 4.1%, Clavien-Dindo grade >/= III morbidity was 29.9%, median (IQR) length of stay 12 (9-18) days, and readmission rate 16.0%. In total 97.2% of >40,000 variables validated were consistent with the medical charts. CONCLUSIONS: The Dutch Pancreatic Cancer Audit, with high quality data, reports good outcomes of pancreatic surgery on a national level.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e74c80d89bdb8e89d1cfce180e01c048Test
http://hdl.handle.net/1887/95336Test

المؤلفون: Ignace H. J. T. de Hingh, Misha D. P. Luyer, Sebastiaan Festen, Bas Groot Koerkamp, Geert Kazemier, Erwin van der Harst, Daphne Roos, Mohammed Abu Hilal, Thijs de Rooij, Gijs A. Patijn, Daan J. Lips, Ruben H J de Kleine, George P. van der Schelling, Pascal Steenvoorde, Casper H.J. van Eijck, Joost M. Klaase, I. Quintus Molenaar, Djamila Boerma, Cornelis J. H. M. van Laarhoven, Jan H. Wijsman, Dirk J. Gouma, Olivier R. Busch, Marc G. Besselink, Menno R. Vriens, Freek Daams, Ronald M. van Dam, Jony van Hilst, Bert A. Bonsing, Marcel G. W. Dijkgraaf, Joris J. Scheepers, Michael F. Gerhards

المساهمون: Surgery, CCA - Evaluation of Cancer Care, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA -Cancer Center Amsterdam, Graduate School, Clinical Research Unit, Other departments, Groningen Institute for Organ Transplantation (GIOT), Value, Affordability and Sustainability (VALUE), RS: NUTRIM School of Nutrition and Translational Research in Metabolism, RS: NUTRIM - R2 - Gut-liver homeostasis, MUMC+: MA Heelkunde (9)

المصدر: Annals of Surgery, 264(5), 754-762. Lippincott Williams and Wilkins
Annals of Surgery, 264(5), 754-762. Lippincott Williams & Wilkins
Annals of surgery, 264(5), 754-762. Lippincott Williams and Wilkins
Annals of Surgery, 264(5), 754-762. LIPPINCOTT WILLIAMS & WILKINS
Annals of Surgery, 264, 754-762
de Rooij, T, van Hilst, J, Boerma, D, Bonsing, B A, Daams, F, van Dam, R M, Dijkgraaf, M G, van Eijck, C H, Festen, S, Gerhards, M F, Koerkamp, B G, van der Harst, E, de Hingh, I H, Kazemier, G, Klaase, J, de Kleine, R H, van Laarhoven, C J, Lips, D J, Luyer, M D, Molenaar, I Q, Patijn, G A, Roos, D, Scheepers, J J, van der Schelling, G P, Steenvoorde, P, Vriens, M R, Wijsman, J H, Gouma, D J, Busch, O R, Hilal, M A & Besselink, M G 2016, ' Impact of a Nationwide Training Program in Minimally Invasive Distal Pancreatectomy (LAELAPS) ', Annals of Surgery, vol. 264, no. 5, pp. 754-762 . https://doi.org/10.1097/SLA.0000000000001888Test
Annals of Surgery, 264, 5, pp. 754-762
Annals of Surgery, 264(5), 754-762

مصطلحات موضوعية: Laparoscopic surgery, Male, Pancreatic disease, medicine.medical_treatment, pancreatic cancer, INTERNATIONAL STUDY-GROUP, REALITY SIMULATOR, 030230 surgery, Cohort Studies, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, Robotic Surgical Procedures, SURGERY ISGPS, distal pancreatectomy, pancreatic surgery, Netherlands, robot-assisted surgery, training, Middle Aged, META-ANALYSIS, laparoscopic surgery, CANCER, Treatment Outcome, 030220 oncology & carcinogenesis, Pancreatectomy, Female, Training program, Distal pancreatectomy, Cohort study, Adult, medicine.medical_specialty, CADAVER, education, DUCTAL ADENOCARCINOMA, CONTROLLED-TRIAL, 03 medical and health sciences, Blood loss, Pancreatic cancer, Pancreatitis, Chronic, medicine, Humans, METAANALYSIS, Aged, business.industry, medicine.disease, Surgery, Pancreatic Neoplasms, DEFINITION, Controlled Before-After Studies, Feasibility Studies, Laparoscopy, business, pancreatic disease

الوصف: Item does not contain fulltext OBJECTIVE: To study the feasibility and impact of a nationwide training program in minimally invasive distal pancreatectomy (MIDP). SUMMARY OF BACKGROUND DATA: Superior outcomes of MIDP compared with open distal pancreatectomy have been reported. In the Netherlands (2005 to 2013) only 10% of distal pancreatectomies were in a minimally invasive fashion and 85% of surgeons welcomed MIDP training. The feasibility and impact of a nationwide training program is unknown. METHODS: From 2014 to 2015, 32 pancreatic surgeons from 17 centers participated in a nationwide training program in MIDP, including detailed technique description, video training, and proctoring on-site. Outcomes of MIDP before training (2005-2013) were compared with outcomes after training (2014-2015). RESULTS: In total, 201 patients were included; 71 underwent MIDP in 9 years before training versus 130 in 22 months after training (7-fold increase, P < 0.001). The conversion rate (38% [n = 27] vs 8% [n = 11], P < 0.001) and blood loss were lower after training and more pancreatic adenocarcinomas were resected (7 [10%] vs 28 [22%], P = 0.03), with comparable R0-resection rates (4/7 [57%] vs 19/28 [68%], P = 0.67). Clavien-Dindo score >/=III complications (15 [21%] vs 19 [15%], P = 0.24) and pancreatic fistulas (20 [28%] vs 41 [32%], P = 0.62) were not significantly different. Length of hospital stay was shorter after training (9 [7-12] vs 7 [5-8] days, P < 0.001). Thirty-day mortality was 3% vs 0% (P = 0.12). CONCLUSION: A nationwide MIDP training program was feasible and followed by a steep increase in the use of MIDP, also in patients with pancreatic cancer, and decreased conversion rates. Future studies should determine whether such a training program is applicable in other settings.

وصف الملف: text

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2782cfa9240c058c8b0597abbe046539Test
https://pubmed.ncbi.nlm.nih.gov/27741008Test

المؤلفون: Eva B. Deerenberg, Sjam Ganesh, John J. Hermans, Casper H.J. van Eijck, Erwin van der Harst, Jan-Werner Poley

المساهمون: Surgery, Gastroenterology & Hepatology, Radiology & Nuclear Medicine

المصدر: Digestive Surgery, 28(5-6), 398-403. Karger

مصطلحات موضوعية: Adenoma, Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Adenocarcinoma, Gastroenterology, Endosonography, SDG 3 - Good Health and Well-being, Predictive Value of Tests, Internal medicine, Pancreatic cancer, Multidetector Computed Tomography, medicine, Pancreatic mass, Humans, cardiovascular diseases, Aged, Retrospective Studies, Aged, 80 and over, Cholestasis, business.industry, Middle Aged, medicine.disease, Pancreaticoduodenectomy, digestive system diseases, Major duodenal papilla, Pancreatic Neoplasms, Predictive value of tests, cardiovascular system, Pancreatitis, Surgery, Female, Radiology, business

الوصف: Background: In some patients suspected of pancreatic cancer, no mass can be detected by multidetector computed tomography (MDCT) scan as the cause of biliary obstruction. Methods: All patients suspected of pancreatic cancer between January 2007 and 2009 with a negative MDCT were identified from a database. Results: MDCT was performed for suspected pancreatic cancer in 290 patients, and in 258 a pancreatic mass was found. MDCT failed to establish a diagnosis in 32 patients (11%). In 23 patients (74%) with complete endoscopic ultrasonography (EUS), the cause of the obstruction was correctly diagnosed. A mass in the pancreatic head was found in 15 patients; 13 patients had a malignant tumor, and 2 patients a benign cause of obstruction. Further, EUS diagnosed 3 patients with a superficial adenoma of the papilla and 8 patients with a benign cause of the obstruction. In 5 patients EUS could not detect the cause of obstruction but finally a pancreatic malignancy was diagnosed. The positive predictive value of EUS was 86% and the negative predictive value 63%. Accuracy of MDCT and EUS decreased in the presence of pancreatitis or a biliary endoprosthesis. Conclusion: In patients suspected of pancreatic cancer in whom MDCT fails to demonstrate the cause of obstructive jaundice, EUS identifies 74% of the underlying diseases correctly.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897e1713640ab04ee027bc98439de9d9Test
https://pure.eur.nl/en/publications/2d0428f5-9274-464e-86b9-5d97319e4780Test